AUS
NZ
UK
CA
USA
IND
Highlights:
- Healius’ CEO and manging director, Malcolm Parmenter will step down from his position from 1 March 2023.
- Existing CFO and COO, Maxine Jaquet will be the new CEO of Healius.
- Healius has sold its Montserrat Day Hospital to Nexus Hospitals for an enterprise value of around AU$138.6 million.
Australian healthcare company Healius Limited (ASX:HLS) shared on Friday (9 December 2022) that its CEO and managing director will step down next year. The pathology and imaging company also informed the ASX that it has signed a binding agreement to sell its Montserrat Day Hospital to Nexus Hospitals for an enterprise value of approximately AU$138.6 million.
Healius shares were spotted trading 1.74% lower at AU$2.83 apiece at 10:49 AM AEDT with a market capitalisation of AU$1.87 billion. In the past five trading sessions, the share price has dropped by 5.90%, and in the last six months, it has decreased by 23.67%. On a year-to-date basis, it has declined by 44.49%, and the yearly fall is 40.70%.
Stepping down of Healius CEO
Healius CEO and managing director, Malcolm Parmenter will leave his position, with Maxine Jaquet taking up his roles and responsibilities from 1 March 2023. Maxine Jaquet is the current chief financial officer and chief operating officer of Healius.
Parmenter has been CEO since September 2017. Jenny Macdonald, chairperson, Healius commented,
On the appointment of Maxine as the new CEO, Macdonald stated that she had played a significant role in portfolio reshaping, divesting medical centres, refocusing the group as a diagnostic operator, improving cash generation, fortifying the balance sheet and structurally improving margins.
According to ASX announcement, the fixed annual remuneration of Jaquet will be AU$1.5 million per annum. For the financial year 2023 (FY23), the short-term incentive is AU$1.0 million, and the long-term incentive is a maximum award of AU$1.5 million, subject to the achievement of objectives set by the Board.
Details of Montserrat Day Hospital sale
Today, Healius shared that Nexus Hospitals will acquire 100% of Montserrat, an operator of haematology/oncology clinics and specialist short-stay hospitals, for an enterprise value of AU$138.6 million. The enterprise value includes deferred contingent consideration of around AU$11.4 million.
Funds managed by QIC Limited control Nexus Hospitals.
The company expects to complete the transaction by the first half of the calendar year 2023, subject to certain conditions.
As reported, Healius would offer pathology services to numerous Montserrat facilities with the intent to expand the provision of diagnostic services with Nexus Hospitals.
